

**Amendments to the Claims**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

**Listing of Claims****Claims 1-32. Canceled.**

33. **(Presently Amended)** A method for treating or lessening the advancement, severity, or effects of ~~an autoimmune disease~~ neoplasia, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide complex comprising a first polypeptide selected from a group consisting of

- (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
- (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
- (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;
- (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2

wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue; and

a second polypeptide which is lymphotoxin- $\alpha$ .

**Claims 34-38. Canceled.**

39. **(New)** The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2.

40. **(New)** The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4.

41. **(New)** The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6.

42. **(New)** The method of claim 33, wherein the first polypeptide is a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2, wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.